Clinical Trial

Ultralow Dose PET Imaging for PSMA Expression

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for prostate cancer detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called 18F-DCFPyL and be imaged on a new type of high sensitivity PET scanner for up to 3 hours
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-31.
Status change: Not Yet Recruiting → Recruiting 2025-06-01
Trial Details
NCT Number NCT06904313
Lead Sponsor Akiva Mintz
Conditions Healthy Volunteer, Prostate CA
Enrollment 200 participants
Start Date 2025-05-12
Primary Completion 2030-06-30 (estimated)
Study Completion 2030-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-06-04